Command Palette

Search for a command to run...

Clinical Trials · NCT05813925

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

CompletedPhase 3Semaglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
331
Start date
Apr 2023
Locations
28 sites, Japan, Taiwan
Primary endpoint
Relative Change in Body Weight
View Semaglutide compound reference